Business Context and Reporting Period
Company: OS Therapies Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 2, 2025
Event: Closing of a second warrant exercise inducement and exchange offer.
Key Financial Metrics
- Gross Proceeds: Approximately $3,777,808 (before deducting transaction fees and expenses).
- Shares Exercised: 3,373,043 shares of common stock via Existing Warrants.
- Exercise Price (Existing Warrants): $1.12 per share (reduced to $0.001 for pre-funded exercises).
- Transaction Fees: 1.5% of total gross cash proceeds paid to the Solicitation Agent.
- Use of Proceeds: Accelerating commercial preparations for OST-HER2 (prevention/delay of recurrent pulmonary metastatic osteosarcoma) and general corporate purposes.
Note: This filing does not provide data on revenue, net profit, operating cash flow, margins, total debt, or liquidity ratios.
Material Changes and Transaction Details
The Company entered into inducement offer letter agreements with remaining holders of Existing Warrants (originally issued Dec 31, 2024, and Jan 14, 2025). Key terms include:
- New Warrants Issued: Holders received New Warrants to purchase up to 3,373,043 shares.
- New Warrant Terms: Exercise price of $3.00 per share; immediately exercisable; five-year term.
- Pre-Funding Mechanism: Holders exceeding beneficial ownership limits pre-funded at $1.119 per share, reducing their exercise price to $0.001.
- Registration: Resale of shares underlying Existing Warrants is registered under Forms S-1. A Form S-3 (or S-1) for New Warrants will be filed within 30 days.
Outlook, Risks, and Unusual Items
- Strategic Focus: Proceeds are directed toward commercial preparations for OST-HER2 in the U.S. market.
- Warrant Provisions:
- Forced Exercise: Company may force cash exercise if stock price exceeds 300% of the exercise price for 20 consecutive trading days.
- Anti-Dilution: Exercise price adjusts downward to the greater of the Dilutive Issuance Price or $1.00 if the Company issues equity at a lower price.
- Ownership Limits: Holders generally limited to 4.99% ownership (electable up to 9.99% with notice).
- Unusual Items: The transaction involved a specific inducement structure to encourage cash exercise of existing warrants in exchange for new warrants with a higher strike price.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 1.5% solicitation fee and other transaction expenses.
- Confirm the status of the Form S-3 (or S-1) registration statement for the New Warrants within the 30-day filing window.
- Review the specific terms of the "Dilutive Issuance" adjustment to understand potential future dilution scenarios.
- Monitor the Company's progress on commercial preparations for OST-HER2 as the primary use of funds.
- Check for any subsequent filings regarding the "Delegend Date" or changes to the beneficial ownership limits.